- Home
- GILD vs PBR Comparison
GILD vs PBR Comparison
Compare GILD & PBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- PBR
- Stock Information
- Founded
- GILD 1987
- PBR 1953
- Country
- GILD United States
- PBR Brazil
- Employees
- GILD N/A
- PBR N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- PBR Oil & Gas Production
- Sector
- GILD Health Care
- PBR Energy
- Exchange
- GILD Nasdaq
- PBR Nasdaq
- Market Cap
- GILD 110.9B
- PBR 91.1B
- IPO Year
- GILD 1992
- PBR N/A
- Fundamental
- Price
- GILD $88.46
- PBR $14.45
- Analyst Decision
- GILD Buy
- PBR Strong Buy
- Analyst Count
- GILD 24
- PBR 7
- Target Price
- GILD $93.91
- PBR $18.24
- AVG Volume (30 Days)
- GILD 7.3M
- PBR 14.9M
- Earning Date
- GILD 11-06-2024
- PBR 11-07-2024
- Dividend Yield
- GILD 3.48%
- PBR 11.84%
- EPS Growth
- GILD N/A
- PBR N/A
- EPS
- GILD 0.10
- PBR 1.20
- Revenue
- GILD $28,299,000,000.00
- PBR $92,525,343,651.00
- Revenue This Year
- GILD $5.71
- PBR N/A
- Revenue Next Year
- GILD $0.37
- PBR N/A
- P/E Ratio
- GILD $911.55
- PBR $5.62
- Revenue Growth
- GILD 3.31
- PBR N/A
- 52 Week Low
- GILD $62.07
- PBR $12.90
- 52 Week High
- GILD $98.90
- PBR $17.91
- Technical
- Relative Strength Index (RSI)
- GILD 46.13
- PBR 63.19
- Support Level
- GILD $89.01
- PBR $13.58
- Resistance Level
- GILD $98.90
- PBR $13.72
- Average True Range (ATR)
- GILD 2.11
- PBR 0.28
- MACD
- GILD -0.63
- PBR 0.14
- Stochastic Oscillator
- GILD 8.58
- PBR 96.96
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2023 was 2.8 million barrels of oil equivalent a day (80% oil production), and reserves stood at 10.9 billion boe (85% oil). At end-2023, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.